ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.80
1.57%
Dow Jones
38,239.66
0.40%
Brent Oil
88.165
0.00%
Bitcoin
62,964.06
-1.22%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Fusion Pharmaceuticals Inc (FUSN) Quote

Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc (FUSN)

NASDAQ
21.42
0.02
(0.09%)
Closed April 27 4:00PM
Delayed by 15 minutes
21.42
0.00
(0.00%)
After Hours: 5:59PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
21.42
Bid
21.14
Ask
21.74
Volume
351,216
21.37 Day's Range 21.48
2.31 52 Week Range 21.55
Market Cap
1.478B
Previous Close
21.40
Open
21.40
Last Trade
25
@
21.35
Last Trade Time
Financial Volume
$ 7,524,237
VWAP
21.4234
Average Volume (3m)
2,212,893
Shares Outstanding
68,990,263
Dividend Yield
-
PE Ratio
-16.87
Earnings Per Share (EPS)
-1.27
Revenue
1.46M
Net Profit
-87.61M

About Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monother... Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.fusionpharma.com
Headquarters
Hamilton, Ontario, Can
Founded
1970
Fusion Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker FUSN. The last closing price for Fusion Pharmaceuticals was $21.40. Over the last year, Fusion Pharmaceuticals shares have traded in a share price range of $ 2.31 to $ 21.55.

Fusion Pharmaceuticals currently has 68,990,263 shares outstanding. The market capitalization of Fusion Pharmaceuticals is $1.48 billion. Fusion Pharmaceuticals has a price to earnings ratio (PE ratio) of -16.87.

FUSN Latest News

More News

Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm

Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm PR Newswire NEW YORK, April 26, 2024 NEW YORK, April 26, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation...

19 hours ago
PR Newswire (US)

Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order

Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order PR Newswire HAMILTON, ON and BOSTON, April 25, 2024 HAMILTON, ON and BOSTON, April...

April 25 2024
PR Newswire (US)

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024 PR Newswire HAMILTON, ON and BOSTON...

April 09 2024
PR Newswire (US)

Kuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law Firm

Kuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law Firm PR Newswire NEW YORK, March 20, 2024 NEW YORK, March 20, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...

March 20 2024
PR Newswire (US)

Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates

Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates Canada NewsWire HAMILTON, ON and BOSTON, March 20, 2024 Company recently...

March 20 2024
PR Newswire (Canada)

Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer

Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer Canada NewsWire HAMILTON, ON and BOSTON, March 19, 2024...

March 19 2024
PR Newswire (Canada)

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Canada NewsWire HAMILTON, ON and BOSTON, March 6, 2024 HAMILTON, ON and BOSTON, March 6, 2024 /CNW/...

March 06 2024
PR Newswire (Canada)

Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting

Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting Canada NewsWire HAMILTON, ON and BOSTON, March 5, 2024...

March 05 2024
PR Newswire (Canada)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.170.821.2521.4921.2165666721.38403227CS
40.120.5633802816921.321.5520.97116591421.33922636CS
1210.2191.079393398811.2121.559.09221289318.46346928CS
2617.47442.2784810133.9521.553.75147138515.38603319CS
5217.72478.9189189193.721.552.3178435414.67344095CS
15612.921528.521.551.9832200712.73963999CS
2602.9215.783783783818.521.551.9827112112.85415138CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

FUSN Discussion

View Posts
Monksdream Monksdream 4 weeks ago
FUSN over $20
👍️0
Monksdream Monksdream 1 month ago
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
March 19 2024 - 03:00AM
PR Newswire (US)
Alert
Print
Share On Facebook
Transaction includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate cancer, pipeline of radioconjugates and state-of-the-art R&D and manufacturing facilities

Fusion shareholders to receive $21.00 per share in cash at closing plus a non-transferrable contingent value right (CVR) of $3.00 per share, representing a total transaction value of approximately $2.4 billion including the CVR

HAMILTON, ON and BOSTON, March 19, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced the Company has entered into a definitive agreement to be acquired by AstraZeneca. The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.
👍️0
Monksdream Monksdream 3 months ago
FUSN new 52 week high
👍️0

Your Recent History

NASDAQ
FUSN
Fusion Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved